Controlled-release nanotherapeutics: State of translation

被引:53
作者
Tan, Yang Fei [1 ]
Lao, Luciana Lisa [1 ]
Xiong, Gordon Minru [1 ]
Venkatraman, Subbu [1 ,2 ,3 ,4 ]
机构
[1] Nanyang Technol Univ, Sch Mat Sci & Engn, Singapore, Singapore
[2] Nanyang Technol Univ, Ocular Therapeut Engn Ctr, Singapore, Singapore
[3] NTU Northwestern Univ Inst Nanomed, Singapore, Singapore
[4] NTU HealthTech, Singapore, Singapore
关键词
Layer-by-layer nanoparticles; Controlled release; siRNA delivery; Sustained drug release; Controlled protein release; BONE MORPHOGENETIC PROTEIN-2; BY-LAYER NANOPARTICLES; LONG-ACTING INJECTION; OSTEOBLAST DIFFERENTIATION; NANOCRYSTAL TECHNOLOGY; ANTICANCER DRUG; DELIVERY-SYSTEM; SIRNA DELIVERY; INSULIN; PHARMACOKINETICS;
D O I
10.1016/j.jconrel.2018.06.014
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
This is a review of nanotherapeutic systems, specifically those that exhibit controlled release of the encapsulated bioactive compound. The survey includes the delivery of a range of bioactive compounds, from lipophilic small molecules to hydrophilic proteins and siRNA molecules. The research into enabling sustained delivery of these compounds from nanocarriers has been prolific, but clinical success has been harder to achieve. This is partly because achieving true sustained duration of action over several days is difficult when the carrier dimensions become less than about 400 nm, due to the much shorter diffusion path length compared to micron-sized carrier systems. Other options must be sought to control the efflux of incorporated bioactives, particularly when these bioactives have moderate to high hydrophilicity. A few of these options are discussed critically in this review. We also answer the question: is controlled release needed for nanotherapies? We present the case for controlled release in specific conditions, with two examples from our own work: one for treatment of glaucoma, and the second for inhibition of fibrosis following surgery. The former is sustaining the release of a small-molecule lipophilic drug, while the latter focusses on sustained siRNA delivery.
引用
收藏
页码:39 / 48
页数:10
相关论文
共 50 条
[41]   Pharmacodynamic and pharmacokinetic rationales for the development of an oral controlled-release amoxicillin dosage form [J].
Hoffman, A ;
Danenberg, HD ;
Katzhendler, I ;
Shuval, R ;
Gilhar, D ;
Friedman, M .
JOURNAL OF CONTROLLED RELEASE, 1998, 54 (01) :29-37
[42]   Effect of food on the pharmacokinetics of osmotic controlled-release methylphenidate HCl in healthy subjects [J].
Modi, NB ;
Wang, B ;
Hu, WT ;
Gupta, SK .
BIOPHARMACEUTICS & DRUG DISPOSITION, 2000, 21 (01) :23-31
[43]   Bioavailability of a controlled-release cyclobenzaprine tablet and influence of a high fat meal on bioavailability [J].
Gai, M. N. ;
Costa, E. ;
Arancibia, A. .
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2009, 47 (04) :269-274
[44]   Development of a Chlorantraniliprole Microcapsule Formulation with a High Loading Content and Controlled-Release Property [J].
Liu, Baoxia ;
Wang, Yan ;
Yang, Fei ;
Cui, Haixin ;
Wu, Decheng .
JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 2018, 66 (26) :6561-6568
[45]   Pharmacokinetics of a controlled-release misoprostol vaginal insert at term [J].
Rayburn, WF ;
Powers, BL ;
Plasse, TF ;
Carr, D ;
Di Spirito, M .
JOURNAL OF THE SOCIETY FOR GYNECOLOGIC INVESTIGATION, 2006, 13 (02) :112-117
[46]   Synthetic biodegradable polyesters for implantable controlled-release devices [J].
Pothupitiya, Jinal U. ;
Zheng, Christy ;
Saltzman, W. Mark .
EXPERT OPINION ON DRUG DELIVERY, 2022, 19 (10) :1351-1364
[47]   THE INFLUENCE OF FOOD-INTAKE ON THE EFFECT OF 2 CONTROLLED-RELEASE FORMULATIONS OF FUROSEMIDE [J].
PAINTAUD, G ;
ALVAN, G ;
ECKERNAS, SA ;
WAKELKAMP, M ;
GRAHNEN, A .
BIOPHARMACEUTICS & DRUG DISPOSITION, 1995, 16 (03) :221-232
[48]   Formulation and Optimization of a Controlled-Release Tablets of Ketorolac Tromethamine [J].
Khan, Barkat A. ;
Ahmad, Sohaib ;
Uzair, Bushra ;
Faiz, Sumera ;
Haider, Faheem ;
Khan, Muhammad K. ;
Shah, Pervaiz A. ;
Rasul, Akhtar .
LATIN AMERICAN JOURNAL OF PHARMACY, 2018, 37 (12) :2538-2544
[49]   Design of controlled-release formulation for ivermectin using silicone [J].
Maeda, H ;
Brandon, M ;
Sano, A .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2003, 261 (1-2) :9-19
[50]   Pharmacokinetics of a Controlled-Release Misoprostol Vaginal Insert at Term [J].
William F. Rayburn ;
Barbara L. Powers ;
Terry F. Plasse ;
Denis Carr ;
Mike Di Spirito .
The Journal of the Society for Gynecologic Investigation: JSGI, 2006, 13 :112-117